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The first 200 N-terminus amino acids of the L2 capsid protein of BPV-4 (designated L2a) are an effective prophylactic
vaccine against BPV-4 infection. Vaccination with L2a induces the production of virus neutralizing antibodies, and when L2a
antibodies are removed from immune sera, the sera lose their neutralization activity. L2a encodes three dominant B-cell
epitopes, defined as epitope 1 (amino acids 101–120), epitope 2 (aa 131–151), and epitope 3 (aa 151–170). To investigate
whether any of these epitopes are responsible individually or in combination for protection against viral challenge, synthetic
peptides, corresponding to the three epitopes (peptides 11, 14, and 16, respectively) and conjugated to keyhole limpet
hemocyanin (KLH) were tested in vaccination challenge experiments. Calves vaccinated with the three peptides together
showed no evidence of papillomavirus infection; those vaccinated with peptide 14 alone developed only early lesions which
did not progress to proper papillomas and regressed rapidly; those vaccinated with peptide 11 or peptide 16 alone were
not protected and proceeded to develop papillomas. Therefore the three B-cell epitopes are not conventionally ‘‘neutralizing’’
when presented individually, but in combination they form a complex neutralization domain, and, in particular, epitope 2,
represented by peptide 14, encodes a domain responsible for disease prevention. q 1997 Academic Press
INTRODUCTION in animals feeding on bracken fern and exposed to the
immunosuppressants and mutagens present in the plant
Infection of epithelia by certain papillomaviruses (Campo, 1997). During our vaccination studies we have
poses a serious risk of cancer (IARC, 1995). Initially the identified the viral protein E7 as a rejection antigen which
virus induces the development of benign hyperprolifera- induces regression of papillomas (Campo et al., 1993)
tive lesions which, after a protracted lag period, can prog- and have shown that both structural proteins, L1 in its
ress to cancer if stimulated by the appropriate cofactors. native configuration and L2 in a denatured form, are ef-
In humans, infection of the lower genital tract by certain
fective prophylactic vaccines which prevent infection
types of human papillomavirus (HPV) results in preneo-
(Campo et al., 1993; Kirnbauer et al., 1996). L1 and L2
plastic lesions which can develop into cancer, particu-
of cottontail rabbit papillomavirus (CRPV) are likewise
larly in women. It is estimated that HPV is responsible
capable of inducing immunity from CRPV infection
for approximately 90% of all cervical carcinomas (zur
(Breitburd et al., 1995; Lin et al., 1992, 1993; Christensen
Hausen, 1994). Cervical cancer is the most frequent form
et al., 1991, 1996), strongly supporting the idea that simi-
of cancer in women in developing countries (Parkin et
lar prophylactic vaccines can be developed for HPV as
al., 1988). Given the cancer’s association with papillo-
well. BPV-4 L2 is particularly interesting in that: it doesmavirus, an antiviral vaccine would reduce infection and
not require a native conformation (Campo et al., 1993);its potential prognosis.
it is effective in low doses (Campo and Jarrett, 1994); itThe bovine papillomavirus type 4 (BPV-4) system has
induces long lasting immunity (Campo and Jarrett, 1994)been extensively studied as a vaccination model for mu-
and elicits the production of virus neutralizing antibodiescosal HPV (Campo, 1994). Infection of the mucosa of the
(Gaukroger et al., 1996). The neutralization epitopes re-upper gastrointestinal tract of cattle by BPV-4 results in
side in the N-terminus of the molecule, L2a (Chandra-the formation of epithelial papillomas. These benign tu-
chud et al., 1995), where three dominant B-cell epitopesmors can undergo neoplastic progression to carcinomas
have been mapped, epitope 1 at amino acid (aa) 101–
120, epitope 2 at aa 131–151, and epitope 3 at aa 151–
170 (Chandrachud et al., 1995; Knowles et al., 1997).1 To whom correspondence and reprint requests should be ad-
dressed. Fax: /141 942 6521. E-mail: s.campo@udcf.gla.ac.uk. To ascertain whether these epitopes are neutralizing,
2 Present address: Faculty of Medicine and Health Science, Jalan we vaccinated calves with synthetic oligopeptides corre-Datuk Mohd Musa, 94300 Kota Samarahan, Sarawak, Malaysia.
sponding to the epitopes, singly or in combinations. Here3 Present address: Specialist Monitoring Services, 25 Wellington
Business Park, Crowthorne, Berks RG45 6LS, GB. we show that vaccination with either the three peptides
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TABLE 1 prising the three peptides, 50 mg of each KLH-peptide
were used. Young calves, 8–12 months old, of mixedImmunodominant B-Cell Epitopes in BPV-4 L2a
breed, were vaccinated by intramuscular injection with
Epitope 1 (aa 101–120) TGVPIDPAVPDSSIVPLLES two vaccine doses each, 4 weeks apart. Experimental
Epitope 2 (aa 131–151) PGAEIEIIAEVHPPPVYEGPE challenge with BPV-4 was performed two weeks after
Epitope 3 (aa 151–170) EVTIGDIEEPPILEVVPETH the second vaccine dose. Virus particles (1011) were inoc-
ulated at 10 sites in the soft palate as described beforeNote. Amino acids homologous to equivalent regions of HPV-6b L2
(Campo et al., 1993). The calves were examined for papil-are in bold.
lomas at week 6, week 10, and week 13 after challenge.
Animals were bled before vaccination and before chal-
together or the single epitope 2 peptide efficiently pre- lenge, and serum samples were prepared. The calves
vented disease. were cared for in complete accordance with the direc-
tives of the Home Office of Great Britain.
MATERIALS AND METHODS
Analysis of the B-cell response
Synthetic oligopeptides
The humoral immune response to the vaccine peptides
Oligopeptides were synthesized corresponding to the was analyzed by ELISA as described by Chandrachud
B-cell epitopes of L2. Peptide 11 (aa 101–120, epitope et al. (1995) and Knowles et al. (1996). Briefly, wells were
1) was synthesized by ALTA Bioscience (University of coated with 1 mg of each peptide, not conjugated to KLH,
Birmingham, UK) and conjugated to keyhole limpet he- or 1 mg of GST–L2a, in 100 ml of bicarbonate buffer and
mocyanin (KLH) by Thistle Peptides (Glasgow). Peptide incubated overnight. Plates were blocked with 10% fish
14 (aa 131–151, epitope 2) and peptide 16 (aa 151–170, gelatine in PBS/0.5% Tween and then washed several
epitope 3) were synthesized and conjugated to KLH, via times with PBS/0.5% Tween. Doubling sera dilutions
an additional N-terminal cysteine, by AFFINITY Research were made and incubated with plates overnight at 377.
Products Ltd, Exeter. After extensive washing with PBS/0.5% Tween, the sec-
ondary anti-bovine IgG goat antibody, conjugated to alka-
Glutathione-S-transferase–L2a fusion protein line phosphatase, was added to the plates. After further
washings, the substrate was added and the plates wereThe production and purification of bacterially ex-
read at 405 nm in a plate scanner. Titers are defined aspressed GST–L2a was as described by Campo et al.
the serum dilutions that gave 50% of the maximum O.D.(1993) and Chandrachud et al. (1995).
readings.
Vaccination
RESULTS
GST–L2a (330 mg) and 50 mg of each KLH-peptide
were mixed with equal volume of alhydrogel as de- Three dominant B-cell epitopes have been identified
in the N-terminus of BPV-4 L2 (Table 1; Knowles et al.,scribed by Gaukroger et al. (1996). For the vaccine com-
FIG. 1. Lesion numbers in calves 6 weeks after experimental infection with BPV-4.
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FIG. 2. Lesion numbers in calves 10 weeks after experimental infection with BPV-4.
1997). To establish whether all or any of these epitopes visible lesions during the course of the experiment (Figs.
1 and 2). In contrast, three of the six animals vaccinatedare neutralizing, calves were vaccinated prophylactically
with synthetic oligopeptides corresponding to the epi- with KLH-pep11 (group 3) developed stage 1 plaques
and one calf had stage 2 papillomas at week 6; fivetopes. Peptides 11, 14, and 16 correspond, respectively,
to epitopes 1, 2, and 3. Six groups of six calves were calves had lesions at week 10, which were primarily
stage 2 papillomas (Figs. 1 and 2). One calf in this groupused: group 1 was inoculated only with the adjuvant alhy-
drogel; group 2 was vaccinated with GST–L2a; group 3 remained papilloma-free during the course of the experi-
ment. Three of the six calves in group 4, which had beenwith KLH-pep11; group 4 with KLH-pep14; group 5 with
KLH-pep16, and group 6 with the three peptides together vaccinated with KLH-pep14, developed stage 1 lesions
at week 6 (Fig. 1), but all the animals in the group were(KLH-pep11 / 14 / 16). Two vaccine doses were admin-
istered, 4 weeks apart, and then the calves were chal- lesion-free by week 10 (Fig. 2). Four calves in group 5,
vaccinated with KLH-pep16, developed mixed lesions atlenged with BPV-4 2 weeks after the second vaccine
dose. Papilloma development was monitored six, ten, week 6, which were all at stage 2 by week 10 (Figs. 1
and 2), but two animals remained papilloma-free for theand thirteen weeks after challenge.
duration of the experiment. We conclude that peptide 14
Development of papillomas is the major determinant of immunity to viral infection in
the L2a vaccine or in the three-peptide vaccine.
The natural history of BPV-4-induced papillomas en-
compasses four stages (Jarrett, 1985): the first clinical Humoral response to the vaccine
sign of infection is a small translucent dome-shaped le-
Given that immunity from infection is antibody-depen-sion, termed ‘‘plaque’’ or ‘‘stage 1’’; the plaque develops
dent (Gaukroger et al., 1996), the humoral immune re-into a stage 2 lesion which is a typical frondy papilloma
actively producing virus; stage 3 is a later stage of devel-
opment in which virus production decreases, and finally
TABLE 2stage 4 is represented by a regressing papilloma infil-
Antibody Titers in Sera of Vaccinated Calvestrated with immune cells (Knowles et al., 1996). Five of
the six calves in group 1, which had been inoculated
Antigen L2a Pep11 Pep14 Pep16with adjuvant alone, showed typical stage 1 lesions at
week 6 (Fig. 1). By week 10, all of the calves had stage Sera
Preimmune 0 0 0 02 papillomas (Fig. 2), and papilloma development contin-
L2a 87.3 { 15.4 17.4 { 2.8 9.2 { 2.5 9.7 { 1ued at week 13 (data not shown) when the experiment
Pep11 19.7 { 2.1 31.3 { 2.8 0 0
was terminated. As expected, the calves vaccinated with Pep14 17 { 2 0 27.1 { 2 0
Pep16 29.7 { 3.1 0 0 31.5 { 2.1GST–L2a (group 2) were all completely protected from
Pep11 / 14 / 16 28.9 { 3 17.7 { 2.7 12.6 { 2.9 17.4 { 2.7infection (Figs. 1 and 2). Calves in group 6, which had
received the vaccine made with the three KLH-peptides Note. Titers shown are the mean titers in each group of calves { standard
error.were also completely protected and did not develop any
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sponse to the peptides in the vaccinated animals was fewer calves with lesions in groups 3 and 5, and fewer
lesions in group 5 as a whole.analyzed by ELISA. The preimmune sera of all animals
did not react with any of the peptides (Table 2), while Although L2a-induced immunity is due to the presence
sera from vaccinated animals responded to peptides. of anti-L2a antibodies in the serum, it appears that these
Sera from L2a-vaccinated animals responded to peptides antibodies do not prevent entry of virus into the cell, as
11, 14, and 16, as reported previously (Knowles et al., viral DNA can be detected in the tissue infected with
1997) (Fig. 3a, Table 2). Similar titers were observed with neutralized virus (Gaukroger et al., 1996). The partial pro-
the sera of animals vaccinated with the three peptides tection from BPV-4 infection in the calves vaccinated with
together (Fig. 3b, Table 2). Calves vaccinated with the peptide 14 is in agreement with these previous results
individual peptides responded with similar titers only to and suggests that anti-peptide 14 antibodies, like anti-
the peptide in the vaccine (Fig. 3c, Table 2) and not to L2a antibodies, do not prevent entry of virus into the cell.
the other two (Table 2). They also responded to L2a Similar results were obtained by Roden and col-
(Table 2), confirming the specificity of the reaction. Thus leagues (1994) who showed that a rabbit antiserum
L2a and the peptides induced the expected humoral re- raised against aa 45–173 of BPV-1 L2, although incapa-
sponse. ble of preventing virus attachment to the cell, prevented
in vitro transformation of C127 cells by BPV-1, again indi-
cating that L2 encodes linear neutralizing epitopes. It
DISCUSSION
has been reported recently that sequences in the N-
terminus of BPV-1 L2 are exposed on the surface of theThree immunodominant B-cell epitopes have been
virion (Liu et al., 1997). One of these sequences, aa 116–identified in the N-terminus of BPV-4 L2. Antibodies to
123, partially overlaps with the neutralization domainepitope 1 are first detected in bovine sera 7 days after
identified by Roden and colleagues (1994), and with epi-a second vaccine dose (Chandrachud et al., 1995), while
tope 1 of BPV-4 L2, which may likewise be displayed onantibodies to all three epitopes are detected 14 days after
the virion surface. The location of L2 epitopes in the BPV-the second dose and before virus challenge (Knowles et
4 virion is being investigated.al., 1997). The reason for this asynchronous antibody
It is interesting that a similar region in the N-terminusproduction is not known, but may have a bearing on
of L2 is recognized by serum antibodies of guinea pigsprevention of infection. As this is antibody-mediated
immunized with HPV-33 L2, and these antibodies cross-(Gaukroger et al., 1996), it was clearly important to verify
react with L2 proteins of HPV-11, -16, and -18 (Volperswhich of these epitopes, if any, is a virus neutralization
et al., 1993). Moreover, antibodies against equivalent re-determinant, by direct vaccination experiments with pep-
gions of HPV-6 and HPV-11 L2 proteins have been de-tides corresponding to the epitopes.
tected in the sera of patients with condyloma acumina-From the results presented above, we conclude that
tum or cervical cancer (Yaegashi et al., 1992). Thesepeptide 14 is the major determinant of immunity to viral
findings indicate that the N-terminus of the L2 proteinsinfection in the L2a vaccine or in the three-peptide vac-
of several HPVs is immunodominant and may containcine. Peptide 11 and peptide 16 seem to contribute little
neutralizing epitopes as is the case for BPV L2 (Gauk-to immunity. Indeed removal of antibodies against pep-
roger et al., 1996; Chandrachud et al., 1995; Roden ettides 11 or 16 from virus-neutralizing immune serum sam-
al., 1994). Paradoxically, the highest sequence homologyples from L2a-vaccinated calves did not abrogate the
between the N-termini of BPV-4 and HPV L2 is displayedserum neutralizing activity (data not shown), confirming
by peptide 11 (see Table 1), and indeed immune bovinethe little impact of these epitopes to virus neutralization
sera from L2a-vaccinated calves recognize an equivalentand immunity. The effect of the removal of anti-peptide
peptide (SDPSIVSLv/IEES) from HPV-16 and HPV-6b L214 antibodies from L2a-immune sera was not assessed.
(data not shown). Single peptides from viral proteins haveIt is to be noticed that in L2a-vaccinated calves or in
already been used in studies of immune responses. Vac-calves vaccinated with the three peptides together, pro-
cination of woodchucks with a peptide containing a T-celltection from infection was complete, whereas in peptide
epitope from the core protein of the woodchuck hepatitis14-vaccinated animals infection appeared to develop in
virus protected the animals from viral infection (Menne etthree calves but then regressed. Other portions of L2a,
al., 1997). Vaccination of mice with a peptide containing aincluding peptide 11 and 16, may thus provide additional
determinants of protection, as perhaps suggested by cytotoxic T-cell epitope from the oncoprotein E7 of HPV-
FIG. 3. Humoral immune response to peptides. The sera were tested 2 weeks after the second vaccine dose, before virus challenge. (a) Antibody
titers to peptides in sera of calves vaccinated with L2a; (b) antibody titers to peptides in sera of calves vaccinated with the three peptides together;
(c) antibody titers to peptide 11, peptide 14, or peptide 16 in sera of calves vaccinated with KLH-pep11, KLH-pep14, or KLH-pep16, respectively; no
response was observed to peptides other than the one used in the vaccine (Table 2). Each symbol represents an individual animal.
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